Empastar 25 mg (Tablet)

Unit Price: ৳ 40.00 (1 x 10: ৳ 400.00)
Strip Price: ৳ 400.00

Medicine Details

Category Details
Generic Empagliflozin
Company Goodman pharmaceuticals ltd
Also available as
Empastar 10 mg tablet

Title

  • Empastar 25 mg Tablet

Categories

  • Medicine
  • Diabetes Management

Description

  • Empastar is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Dosage

  • The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily.

Pharmacology

  • Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor which reduces renal absorption of glucose, resulting in increased glucose excretion, reduced hyperglycemia, weight loss, and reduced blood pressure.

Interaction

  • Co-administration with diuretics results in increased urine volume. Co-administration with insulin or insulin secretagogues increases the risk for hypoglycemia. Monitoring glycemic control with urine glucose tests and 1,5-anhydroglucitol (1,5-AG) assay is not recommended.

Contraindications

  • History of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.

Side Effects

  • Common adverse reactions include urinary tract infections, female genital mycotic infections, dehydration, hypotension, weakness, dizziness, and increased thirstiness.

Pregnancy & Lactation

  • Not enough data on use in pregnant women. Not recommended during breastfeeding.

Precautions & Warnings

  • Assessment of renal function is recommended prior to initiation of Empastar and periodically thereafter. Should not be initiated in patients with an eGFR less than 45 ml/min/1.73 m^2.

Overdose Effects

  • Supportive measures should be employed in the event of an overdose with Empastar. Removal of Empastar by hemodialysis has not been studied.

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

Chemical Structure

  • Molecular Formula: C23H27ClO7

Indications

  • Improving glycemic control in adults with type 2 diabetes mellitus and reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Mode of Action

  • Inhibition of sodium glucose co-transporter-2 (SGLT-2) results in reduced renal absorption of glucose, leading to increased glucose excretion, weight loss, and reduced hyperglycemia.

Diuretics Interaction

  • Results in increased urine volume when co-administered with Empastar.

Insulin Interaction

  • Increases the risk for hypoglycemia when co-administered with Empastar.

Urine Glucose Test

  • Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors.

1,5-anhydroglucitol (1,5-AG) Assay

  • Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.

Hypersensitivity Reaction

  • Contraindicated in patients with a history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients.

Renal Impairment

  • Contraindicated in patients with severe renal impairment or end-stage renal disease.

Blood Pressure

  • Reduces blood pressure as a result of its pharmacological action.

Dehydration

  • Common adverse reaction associated with Empastar.

Weight Loss

  • A potential benefit of Empastar's pharmacological action.

Female Genital Mycotic Infections

  • Common adverse reaction associated with Empastar.

1,5-AG

  • Abbreviation for 1,5-anhydroglucitol assay.

Assessment of Renal Function

  • Recommended prior to initiation of Empastar and periodically thereafter.

EGFR

  • Estimated Glomerular Filtration Rate, used as a criterion for initiation of Empastar.

Supportive Measures

  • Employed in the event of an overdose with Empastar.

Hemodialysis

  • Removal of Empastar by hemodialysis has not been studied.

Hygiene

  • Practice good hygiene to prevent genital fungal and/or urinary tract infections associated with Empastar.

Blood Sugar Monitoring

  • Regular monitoring is recommended while taking Empastar.

Medical Emergency Symptoms

  • Symptoms such as constant dizziness, joint pain, cold-like symptoms, or unexplained nausea/vomiting should be reported to the doctor immediately.

SGLT-2 Inhibitor

  • Class of drug to which Empastar belongs.

Molecular Formula

  • C23H27ClO7

Cool & Dry Place

  • Recommended storage conditions for Empastar.

Light & Moisture Protection

  • Recommended storage conditions for Empastar.

Keep Out of Reach of Children

  • Recommended storage conditions for Empastar.

Related Brands